Am currently Trading with Mr. Henry Artem trade a crypto assistant who has been in the crypto market for over 8years. I don’t do many advocates about people on this platform, regardless am using this opportunity to reach out to every investor or newbies that need guidance on crypto investment and trading in building their portfolio to reach out to Mr. Henry Artem Trade. I have made over 450k profits from a 70k investment. Reach out to him on 🆃🅴🅻🅴🅶🆁🅼 (HENRYARTEM).
M
Good earnings. I've seen new paper with results from their second gen vaccine. Its multivalent and cross neutralizing all covid variants. Hope it will be publicated soon. Hope GSK collaboration will make the approval fast!
S
CVAC looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
O
Curevac vaccine is the future! Moderna, Pfizer and novavax are all dead. Only Curevac new vaccine works against all covid variants!
L
Only Curevac is UP because Curevac is the FUTURE!!! Vaccine against all covid variants!
s
this share should be higher than 150#$%$
s
hope to see 150#$%$ soon
M
Why not reach 20$ before the end of the week! We only need one good news! 🤟
J
Monday we GO UP
J
Does anyone know when sec gen phase 1/2 results? Should be soon, should be great.
Curevac vaccine is the future! Moderna, Pfizer and novavax are all dead. Only Curevac new vaccine works against all covid variants.
J
There are so many products in pipe like, looks like they want to be Amazon of cures but they don’t have any cure yet. It cost $2 billion and 2 years trial before FDA can approve anything. Their goal is not realistic. Sorry Bill Gates, you should stick with making a better computer.
Y
CureVac is up 8.24% to 17.33
Y
CureVac is up 9.14% to 18.03
E
BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.
Germany will pay upward of 2.86 billion euros ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. Wednesday, the German government approved plans to sign contracts with mRNA specialist BioNTech plus the partnership between CureVac and GlaxoSmithKline. Also involved are contract manufacturers Wacker, CordenPharma, Celonic and IDT, the news outlet said.
B
The EU Commission has signed a contract with the Tübingen-based company Curevac for the purchase of up to 405 million doses of corona vaccine.
G
My take on today's fall: CVAC is not a cheap stock and after a few days worth of reasonable gains there will be instant downward pressure. There are a lot of retail investors in this stock too. This will attract a degree of day traders possibly short selling and spooking longs to make a quick buck. But the fundamentals have NOT changed. And the information we get from CVAC and elsewhere is only positive. Regarding variants CVAC has already done lab tests on the SA variant and results were excellent. I see no good reason to sell, I'd buy more if I could.
E
Please help: Why CureVac is going that much up without having a product on the street.
G
published today, a new interview with Kremsner. Two key quotes: "he expects data that are similar to those of other mRNA vaccines" + “It looks good,” says the Austrian Kremsner on the phone. The crucial phase III study should be completed “soon”, probably in May. + "Curevac predicts that the current problems with the supply of raw materials and equipment from the USA will not reduce production volumes this year." + “We are therefore reaffirming our production forecast of 300 million doses of our vaccine candidate CVnCoV in 2021,” explains a company spokeswoman.
https://assets.wallstreet-online.de/_media/8763/board/20220328161124-screenshot-2022-03-28-at-16-10-45-powerpoint-pres.png
#++#+
Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.
Germany will pay upward of 2.86 billion euros ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. Wednesday, the German government approved plans to sign contracts with mRNA specialist BioNTech plus the partnership between CureVac and GlaxoSmithKline. Also involved are contract manufacturers Wacker, CordenPharma, Celonic and IDT, the news outlet said.